Last reviewed · How we verify
intensive group
At a glance
| Generic name | intensive group |
|---|---|
| Also known as | intensive Lipitor |
| Sponsor | Shenyang Northern Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- "Improving Health and Reducing Chronic Disease Risk in Middle-Aged Adults Through Nutrition" (NA)
- Prospective Validation of a Pre-Specified Algorithm for the Management of Conduction Disturbances Following TAVR
- Virtual Reality (VR) NATURE - Alcohol Use Disorder (AUD) (NA)
- KD Treatment for Super-refractory Status Epilepticus (NA)
- Canadian Critical Care Comparative Effectiveness Platform (PHASE3)
- Effects of Intensive Virtual Reality-Based Balance and Gait Training on Activity Performance and Quality of Life in Subacute Stroke Patients (NA)
- Management of Catatonic Features in Adolescents With Profound Autism (NA)
- Immediate Versus Substantiated Antibiotic Therapy in Suspected Non-Severe Ventilator-Associated Pneumonia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- intensive group CI brief — competitive landscape report
- intensive group updates RSS · CI watch RSS
- Shenyang Northern Hospital portfolio CI